Ambulero Raises Up To $5.5 Million from Orphinic Scientific Miami Cell and Gene Therapy Company Opens European Subsidiary To Advance Gene Therapy For Rare Vascular Disease
January 25, 2021 21:46 ET | Source: Ambulero Ambulero Miami, Florida, UNITED STATES
MIAMI, Jan. 25, 2021 (GLOBE NEWSWIRE) Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease, today announced that it raised up to $5.5M in funding from Orphinic Scientific (“Orphinic”). As part of the investment, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.
Published: Jan 26, 2021
MIAMI, Jan. 25, 2021 (GLOBE NEWSWIRE)
Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease, today announced that it raised up to $5.5M in funding from Orphinic Scientific (“Orphinic”). As part of the investment, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.
Ambulero holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Omaida C. Velazquez and Jun Zhao-Liu. That research demonstrated in relevant animal models that an important cell adhesion molecule (E-selectin) can help promote vascular repair.
Through the fourth quarter of 2020, businesses in Aiken received $15.1 million in health-related relief from the CARES act issued by the Department of Health and Human Services.
According to numbers reported through the fourth quarter of 2020, businesses in South Carolina received $1.2 billion in health-related relief from the CARES act issued by the Department of Health and Human Services. The largest recipient of funding in the state was Prisma Health-Upstate with a total of $131 million. The average loan size in the city was $145,137 while the state s average loan amount was $258,718.
Of the money distributed, $30 billion went out automatically to health providers based on previous year medicare payments. If the money wasn t returned within 90 days the provider is then automatically entered into the repayment terms that are issued by HHS. With the money going out automatically and the rules constantly changing, some of the businesses that received the money weren t eligible to r